



International Society of Pharmacovigilance

Guidelines for ISoP Alliances and Partnership with Health Partners

Version 1 dated July 2025	Responsible Angela Caro-Rojas, President Brian Edwards, Vice-president Omar Aimer, Treasurer Mónica Tarapués, Secretary-General Executive Committee 2022-2025 <i>ISoP Administration</i>
Approval date: October 2025	Advisory Board 2022-2025

Table of Contents

1. **Document Objective**
2. **Scientific Objective**
3. **Rationale for Implementation**
4. **Definition of Health Partners**
5. **ISoP Global Allies**
 - a. Public Health and Government Agencies
6. **Regional and Local Allies**
 - a. Healthcare Organizations
 - b. Pharmacovigilance Societies and Foundations
 - c. Academic Institutions
 - d. Patient Organizations
 - e. Health Information Technology (IT) Vendors
 - f. Contract Research Organizations (CROs)
 - g. Pharmaceutical Companies
 - h. Medical Device Manufacturers
 - i. Biotechnology Companies

- j. Clinical/Bio Laboratories
- k. Regulatory Consultancy Firms

7. Strategic Objectives for the ISoP–Health Partner Collaboration

- a. Enhance Patient Safety
- b. Knowledge Exchange
- c. Educational Initiatives
- d. Resource Sharing
- e. Awareness and Promotion of Medication Safety Culture
- f. Support for Research Projects

8. Ethical Framework for Collaboration

- a. Compliance with ISoP Bylaws and Code of Conduct
- b. Mutual Respect and Transparency
- c. Integrity and Independence
- d. Conflict of Interest Mitigation
- e. Patient-Centric Approach
- f. No Product Endorsement
- g. Regular Review and Feedback
- h. Compliance with MedTech and Ethical Guidelines

9. Benefits for Health Partners

- a. Enhanced Public Image
- b. Collaborative Research Opportunities
- c. Consumer and Patient Safety Insights
- d. Guidance on Regulatory Requirements
- e. Access to Educational Opportunities

10. Options for Interaction with ISoP

- a. Discounts in group membership
- b. Annual Partnerships for ISoP Events
- c. Special Projects

1. **Document objective:** To establish the rules for having a relationship between ISoP and the stakeholders who have an interest in advancing pharmacovigilance.
2. **Scientific Objective:** The primary objective of this strategy is to establish formalized considerations for alliances and partnerships between ISoP and a broad range of health partners. This initiative aims to foster collaboration on patient safety, advance research and educational initiatives, and enhance the overall quality of healthcare systems through mutual knowledge exchange and if needed, resource sharing. By integrating these partnerships, ISoP seeks to achieve tangible improvements in patient safety standards, clinical outcomes, and healthcare delivery.
3. **Rationale for Implementation:** The establishment of these alliances and partnerships is critical to enabling ISoP to leverage the unique capabilities, resources, and expertise of its health partners. With a focus on enhancing patient safety, the partnership will drive the development of innovative solutions, promote best practices, and foster a deeper understanding of the challenges and opportunities in medication safety topics. This program will allow ISoP to strengthen its research capacity, deliver more impactful educational programs, and create lasting relationships with key stakeholders across the healthcare sector. The benefits for partners are just what is included in this document and never could go against to the ISoP bylaws.
4. **Defining Health Partners:**
5. **ISoP Global Allies**
 - a. **Public Health and Government Agencies:** Global Non Profit Organizations with high impact in health and Medication Safety, which develop health policies, monitor public health issues, and regulate healthcare services and products, making them important allies in patient safety. It includes World Health Organization (WHO), Uppsala Monitoring Centre (UMC), Council for International Organizations of Medical Sciences (CIOMS), these organizations are considered as natural partners of ISoP, they have a particular treatment for ISoP included in individual MoUs.
6. **Regional and local allies**
 - a. **Healthcare Organizations:** Institutions like hospitals, clinics, and nursing homes deliver preventive, curative, and palliative care, making them vital partners in improving patient safety outcomes.
 - b. **Pharmacovigilance Societies and foundations:** Non Profit Organizations which work locally in advance pharmacovigilance in countries of regions.

- c. **Academic Institutions:** Academic institutions contribute to biomedical and clinical research, offering insights and innovations that enhance healthcare technologies and treatments.
- d. **Patient Organizations:** These groups advocate for patient interests, raise awareness, promote research, and influence healthcare policy, ensuring that the patient voice remains central in healthcare decision-making.
- e. **Health Information Technology (IT) Vendors:** Companies providing software solutions for managing healthcare data are key in modernizing healthcare systems and enhancing patient safety through improved data management and telemedicine services.
- f. **Contract Research Organizations (CROs):** CROs support pharmaceutical, biotechnology, and medical device industries through clinical trials and research services, facilitating the development of safer healthcare products.
- g. **Pharmaceutical Companies:** Pharmaceutical companies are essential for developing, producing, and marketing drugs licensed for use as medications. Their expertise ensures the availability of safe, effective, and high-quality medicines for patients.
- h. **Medical Device Manufacturers:** These companies design, produce, and supply medical devices such as diagnostic tools and implants that play a critical role in diagnosing, treating, and preventing diseases.
- i. **Biotechnology Companies:** Focusing on biological systems and organisms, biotechnology firms contribute to healthcare advancements through genetic engineering, diagnostics, and biologic treatments.
- j. **Clinical/ Bio Laboratories:** Clinical laboratories provide critical diagnostic services, supporting healthcare delivery by analysing patient specimens to diagnose and prevent diseases.
- k. **Regulatory Consultancy Firms:** These firms provide strategic, operational, and regulatory advice to healthcare organizations, aiding in the implementation of best practices for patient safety and healthcare innovation.

7. **Strategic Objectives for the ISoP-Health Partner Collaboration:**

- a. **Enhance Patient Safety:** The partnership will prioritize patient safety through collaborative research, the development of medication safe use protocols, and the creation of safer medical products and healthcare practices.
- b. **Knowledge Exchange:** Health partners and ISoP will facilitate the exchange of knowledge and best practices, advancing patient safety through shared expertise.
- c. **Educational Initiatives:** Define necessities and support training programs, workshops, and conferences will educate healthcare professionals on the latest medication safety strategies.
- d. **Resource Sharing:** ISoP and health partners will pool resources, including technical expertise and infrastructure, to drive patient safety initiatives and support research and educational projects.
- e. **Awareness and increase of medication safety culture:** To promote communication and campaigns to raise awareness among healthcare professionals, patients, and the public on specific patient safety issues.
- f. **Support for research projects:** Health partners will support research on medication safety strategies and healthcare processes interventions.

8. **Ethical Framework for Collaboration:**

- a. **Respect and follow ISoP bylaws including code of conduct:** As an independent, academic and scientific organization, ISoP follows strictly the defined bylaws. The partners must be aware and follow it.
- b. **Mutual Respect and Transparency:** Both parties will recognize the inherent value of each other's contributions and maintain transparency in all interactions, agreements, and if exist, financial transactions.
- c. **Integrity and Independence:** All collaborations will adhere to high ethical standards. ISoP will maintain its independence in decision-making, recommendations, and research.
- d. **Conflict of Interest Mitigation:** Both parties must declare any potential or actual conflicts of interest and take steps to manage and mitigate them to preserve ISoP's credibility.
- e. **Patient-Centric Approach:** The collaboration must prioritize patient safety and ensure that all outcomes benefit patient well-being.
- f. **No Product Endorsement:** ISoP's membership or partnership with health partners does not imply endorsement of their products or services.

- g. **Regular Review and Feedback:** Partnerships will be reviewed annually to ensure alignment with ethical principles, and stakeholders will be able to provide feedback on the partnership.
 - h. **Med tech Guidelines and Ethical relationships guidelines:** Every relationship must follow all the ethical guidelines.
9. **Benefits for Health Partners:**
- a. **Enhanced Public Image:** Health partners will be recognized for their commitment to patient and medication safety, and as ISoP partners, particularly in events of ISoP as is defined in events guidelines.
 - b. **Collaborative Research:** ISoP's expertise will amplify joint research efforts.
 - c. **Consumer Insights:** Health partners will gain valuable insights into patient safety issues, guiding product innovation.
 - d. **Guidance on Regulations:** ISoP will provide guidance on meeting regulatory requirements related to patient safety.
 - e. **Educational Opportunities:** ISoP will provide educational opportunities to their partners.

10. Option of Interactions

a. Discounts in group membership

It implies the possibility of received discounts if more than 5 people of the same organization, ask for membership in the same year, it would be renewal year by year. Apply for the same category LMIC or HIC. Fees will be:

5 to 9 membership: 10% of discount

10 to 19 membership: 20% of discount

More than 20 membership: 25% of discount

Responsible of the strategy execution: **ISoP administration**

In any case, every member will act in their own name, as persons, considering ISoP is a Society of professionals, they couldn't act in name of their institution. The ideas, opinions and acts of the members couldn't be considered as an organization's representation.

b. Annual Partnership for ISoP events:

It implies to become a partner for supporting ISoP events: Annual Meeting, Patient Safety Day, Intelligent Automation and Midyear Training*, or regional Chapter meetings, including:

- Branding presence in the events
- Possibility of 1 talk participation (speaker/panelist/chairperson) in one of the events (Under Scientific Committee of the event consideration)
- Exhibition physic and/or virtual, space
- Acknowledge in social media.
- 3 Free registration for each in-person event.

*** Reviewed with the host**

**** Particular support and benefits could be discussed and approved by the EC lead by the treasurer**

The value of this package of sponsorship will be defined every year.

Responsible of the strategy: **Treasurer for negotiation, EC for approval and PCO for execution.**

c. Special projects

Some especial projects for increase culture of medication safety, training or research could be managed between ISoP and the partners with clear conditions and, if it is needed, funding. The detail of execution of projects would be discussed under Projects formal documents which must include: Objective, Scope, Justification/ Rational, Methodology, Budget, Schedule, Responsibilities and Benefits for ISoP and the partner, conflict of interest declaration. Every project needs a particular MoU signed by ISoP and the partners considering the Project.

These projects must be related with improve medication safety, ideally focus on vulnerable communities and for supporting Low Income countries. The projects must not be related with commercial promotion or marketing of products/ services. The partner representative for the project, must be an ISoP member.

Responsible of the strategy: The projects must be approved by the Executive Committee and the Scientific Board (SB), and SB will frequently check of the execution and achievement of goals in the timeline.